ENTA - Enanta Pharmaceuticals, Inc.
| Previous Close | 87.23 |
| Open | 87.23 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 900 |
| Day's Range | 86.44 - 89.09 |
| 52 Week Range | 64.08 - 127.77 |
| Volume | 128,189 |
| Avg. Volume | 253,620 |
| Market Cap | 1.725B |
| Beta (3Y Monthly) | 1.71 |
| PE Ratio (TTM) | 21.51 |
| EPS (TTM) | 4.13 |
| Earnings Date | May 7, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 107.17 |
- Business Wire•4 days ago
Enanta Pharmaceuticals to Host Conference Call on May 7th at 4:30 pm ET to Discuss Its Financial Results for Its Fiscal Second Quarter Ended March 31, 2019
Enanta Pharmaceuticals, Inc. (ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal second quarter ended March 31, 2019 after the U.S. markets close on May 7, 2019. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on Enanta’s business, including its research and development pipeline. Enanta will host a conference call and webcast on May 7 at 4:30 p.m. ET.
- Market Realist•11 days ago
VKTX or ENTA: What to Expect from Revenue Growth in 2019
What Are Analysts Recommending for VKTX and ENTA?(Continued from Prior Part)Growth drivers In November 2018, Viking Therapeutics (VKTX) issued a press release announcing positive results from its Phase 2 trial evaluating the efficacy of the 1-mg dose
- Market Realist•11 days ago
What Are Analysts Recommending for VKTX and ENTA?
What Are Analysts Recommending for VKTX and ENTA?Stock price movementOn April 12, Viking Therapeutics (VKTX) closed at $9.35, 6.22% lower than its previous closing price, 153.39% higher than its 52-week low of $3.69, and 61.04% below its 52-week
- Business Wire•15 days ago
Enanta Pharmaceuticals Presents New Preclinical Data on Compounds Targeting Hepatitis B Virus and Non-Alcoholic Steatohepatitis at The International Liver Congress™ 2019
Enanta Pharmaceuticals, Inc. (ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced that new preclinical data from Enanta’s wholly-owned development programs for hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH) will be presented at The International Liver Congress™ (ILC) 2019, in Vienna, Austria. New data include a presentation on development candidate EDP-514, Enanta’s core inhibitor for HBV that is expected to enter into a Phase 1 clinical study in the second half of 2019.
CNW Group•15 days agoAbbVie's MAVIRET™ now reimbursed in Quebec
AbbVie's MAVIRET™ now reimbursed in Quebec
- Simply Wall St.•21 days ago
Can You Imagine How Chuffed Enanta Pharmaceuticals's (NASDAQ:ENTA) Shareholders Feel About Its 216% Share Price Gain?
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a com...
CNW Group•22 days agoAbbVie Announces New Formulary Listings for its Hepatitis C Treatment MAVIRET™
AbbVie Announces New Formulary Listings for its Hepatitis C Treatment MAVIRET™
- Zacks•25 days ago
The Zacks Analyst Blog Highlights: Celgene, Puma, Exelixis, Enanta and Sage
The Zacks Analyst Blog Highlights: Celgene, Puma, Exelixis, Enanta and Sage
- Business Wire•last month
Enanta Pharmaceuticals Announces Data Presentations at The International Liver Congress™ 2019
Enanta Announces Data Presentations at the International Liver Congress 2019
- Business Wire•last month
Enanta Pharmaceuticals Completes Enrollment in Two Ongoing Phase 2 Studies
Enanta Pharmaceuticals, Inc. (ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced it has completed enrollment in two Phase 2 studies. The Phase 2 study of EDP-938 in RSV is a randomized, double-blind, placebo-controlled, human challenge study in healthy adult subjects randomized into 1 of 2 dosing arms or a placebo arm. Subjects are dosed for 5 days and receive a once-daily 600 mg dose, a single 500 mg loading dose followed by 300 mg twice daily, or placebo.
- Business Wire•2 months ago
Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences
Enanta Pharmaceuticals, Inc. , a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R.
- GlobeNewswire•2 months ago
Factors of Influence in 2019, Key Indicators and Opportunity within BCE, Nektar Therapeutics, Hormel Foods, Enanta Pharmaceuticals, MongoDB, and Regal Beloit — New Research Emphasizes Economic Growth
NEW YORK, Feb. 15, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of ENTA earnings conference call or presentation 6-Feb-19 9:30pm GMT
Q1 2019 Enanta Pharmaceuticals Inc Earnings Call
Motley Fool•3 months agoEnanta Pharmaceuticals Inc (ENTA) Q1 2019 Earnings Conference Call Transcript
ENTA earnings call for the period ending December 31, 2018.
- Zacks•3 months ago
Enanta Pharmaceuticals (ENTA) Lags Q1 Earnings and Revenue Estimates
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -14.38% and -4.34%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•3 months ago
Enanta Pharmaceuticals: Fiscal 1Q Earnings Snapshot
The Watertown, Massachusetts-based company said it had net income of $1.25 per share. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
- Business Wire•3 months ago
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter and Three Months Ended December 31, 2018
Webcast and Conference Call today at 4:30 p.m. ET
- Zacks•3 months ago
Enanta Pharmaceuticals (ENTA) Earnings Expected to Grow: Should You Buy?
Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.•3 months ago
Do You Like Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) At This P/E Ratio?
This article is written for those who want to get better at using price to earnings ratios (P/E ratios). To keep it practical, we'll show how Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) Read More...
- Business Wire•3 months ago
Enanta Pharmaceuticals to Host Conference Call on February 6th at 4:30 pm ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2018
Enanta Pharmaceuticals, Inc. (ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal first quarter ended December 31, 2018 after the U.S. markets close on February 6, 2019. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on Enanta’s business, including its research and development pipeline. Enanta will host a conference call and webcast on February 6 at 4:30 p.m. ET.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of ENTA earnings conference call or presentation 26-Nov-18 9:30pm GMT
Q4 2018 Enanta Pharmaceuticals Inc Earnings Call
- Business Wire•4 months ago
Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and Business Outlook for 2019 during the 37th Annual J.P. Morgan Healthcare Conference
Enanta Pharmaceuticals, Inc. (ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., Enanta’s President and Chief Executive Officer, will provide an update on its research and development programs in respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH)/primary biliary cholangitis (PBC), and discuss its business outlook for 2019 during Enanta’s presentation at the 37th Annual J.P. Morgan Healthcare Conference on January 7, 2019 at 4:30 p.m. Pacific time.
- Business Wire•4 months ago
Enanta Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference
Enanta Pharmaceuticals, Inc. (ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., Enanta’s President and Chief Executive Officer will make a formal presentation at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 4:30 p.m. Pacific Time. The presentation will contain a business overview and an update on Enanta’s research and development programs.
- Insider Monkey•4 months ago
Here is What Hedge Funds Think About Enanta Pharmaceuticals Inc (ENTA)
Is Enanta Pharmaceuticals Inc (NASDAQ:ENTA) a good bet right now? We like to analyze hedge fund sentiment before doing days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy league graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage […]
- Simply Wall St.•5 months ago
Is Enanta Pharmaceuticals Inc’s (NASDAQ:ENTA) CEO Pay Fair?
Jay Luly has been the CEO of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) since 2003. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Then Read More...
